This is indeed the case as demonstrated by a recent clinical trial in which patients with BRCA1/2 mutated, PARP inhibitor‐resistant ovarian cancers showed a robust response to platinum‐based therapies (Ang et al, 2013). This evidence concerns the gene PARP1 and ovarian cancer.